Indivior Directorate Changes
Slough, UK and Richmond, VA, 31 July 2019 – The Board of Indivior PLC is pleased to announce the appointment of Peter Bains as an independent Non-Executive Director of the Company with effect from 1 August 2019. Peter will also be appointed as a member of the Audit and Science & Policy Committees with effect from the same date.
The Company announces that Chris Schade will step down from the Board with immediate effect, due to increasing professional commitments as CEO of Aprea Therapeutics. The Company further announces that, due to enhanced professional commitments, Lizabeth Zlatkus has advised that she will step down from the Board with effect from 31 August 2019, following the end of her term of office.
The Board has reviewed its composition and that of its Committees and confirms that a search will be undertaken to identify an additional independent Non-Executive Director. Daniel Tasse, Senior Independent Director, will be appointed Chair of the Audit Committee and Daniel Phelan will step down as a member of the Nomination & Governance Committee and be appointed a member of the Audit Committee on an interim basis; these changes will be effective immediately.
Howard Pien, Chair, commented:
‘Peter will bring significant expertise to the Board having over three decades of experience in the biotech and pharmaceutical industry encompassing strategic and operational leadership expertise across global geographies, function and business segments. We are delighted to welcome him to the Board.’
‘I would also like to thank Liz and Chris for their valuable contributions to the Board and wish them well for the future.’
Peter is currently a director of Mereo Biopharma, a company listed on FTSE AIM and Nasdaq. He was previously representative executive officer and chief executive officer of Sosei Group Corporation (2010-18), a Tokyo listed biotech company, chief executive officer of Syngene International (2010-16) which he successfully took public on the Mumbai exchange in 2015 and a Non-Executive Director of Kromek Limited (2010-15), a FTSE AIM listed company.
There is no further information to disclose in relation to Peter Bains's appointment in accordance with LR 9.6.13.
Note:
No remuneration is payable consequent upon or in respect of the retirements of Lizabeth Zlatkus or Christian Schade. They will receive pro-rated Board and Committee chair/membership fees, as applicable, to the date of their retirement. Neither director will receive any payment for loss of office or any other payments in relation to their retirement.
About Indivior
Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline “Focus on you” makes the Company’s commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and cooccurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.
Contact:
Jason Thompson
Vice President, Investor Relations
jason.thompson@indivior.com
+1 804 402 7123